BioNTech (NASDAQ:BNTX) Announces Earnings Results, Beats Estimates By $0.70 EPS

BioNTech (NASDAQ:BNTX) posted its quarterly earnings data on Monday. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70, RTT News reports. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.90 EPS.

BioNTech Price Performance

BNTX opened at $108.78 on Monday. The stock’s 50-day moving average price is $116.91 and its 200 day moving average price is $112.93. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The firm has a market cap of $26.08 billion, a price-to-earnings ratio of -51.80 and a beta of 0.30. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

Analysts Set New Price Targets

A number of brokerages have recently commented on BNTX. HC Wainwright reiterated a “buy” rating and issued a $150.00 target price on shares of BioNTech in a research report on Monday, November 18th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Truist Financial assumed coverage on BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target for the company. Wells Fargo & Company started coverage on BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price for the company. Finally, Berenberg Bank assumed coverage on BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.